Bio-Gene Advances Flavocide Toward March 2027 Regulatory Submission

Regulatory Progress on Flavocide

Bio-Gene Technology Limited (ASX:BGT) has provided a comprehensive update on the regulatory development of Flavocide, its novel insecticidal active constituent derived from a natural plant compound. The company is advancing a series of toxicology studies designed to underpin its first application for registration with the Australian Pesticides & Veterinary Medicines Authority (APVMA), targeting submission in March 2027.

Flavocide represents a new mode of action in insect control, offering a promising solution to the growing global challenge of insecticide resistance. Bio-Gene’s approach focuses initially on professional and domestic insecticide uses, excluding food production, with an emphasis on controlling disease-vectoring flying insects such as mosquitoes.

Toxicology Studies and Data Generation

The company has completed key preliminary studies, including a 28-day rat repeat dose oral toxicity and a pilot metabolism and pharmacokinetics study, which have supported progression to longer-term and more detailed toxicology assessments. Major ongoing studies include extended one generation reproductive toxicity and acute neurotoxicity tests, with results expected in May and September 2026 respectively.

These studies are conducted to OECD standards, ensuring international regulatory acceptance and facilitating future submissions beyond Australia. Bio-Gene plans to run remaining studies concurrently to meet the planned regulatory filing timeline.

Commercial and Regulatory Outlook

Following the APVMA submission, Bio-Gene anticipates a regulatory review period of up to 18 months, although actual timing may vary. The company also plans to pursue registrations in the United States and other major markets, adapting to jurisdiction-specific data requirements, particularly around environmental fate and ecotoxicology.

Flavocide’s development includes rigorous product chemistry and stability testing, with pilot-scale production completed in India and ongoing batch analyses to support regulatory dossiers. The company’s business model centers on licensing Flavocide to commercial partners who will formulate and register insecticidal products, with Bio-Gene receiving milestone payments and royalties.

Strategic Significance

Managing Director Tim Grogan emphasised the importance of this regulatory milestone, noting that Flavocide’s novel mode of action could provide a vital new tool in integrated pest management strategies worldwide. The successful registration of Flavocide would mark a significant step forward for Bio-Gene’s commercialisation ambitions and its contribution to addressing insecticide resistance challenges.